Trial
NCT03591744
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Plasma Cell Leukemia
Intervention
Bortezomib
Why stopped
Budgetary constraints
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-12-19